Morten Frier Gjerstorff

List of Publications by Year
in descending order

51	1,732	304368	288905
papers	citations	22 h-index	40 g-index

52	52	52	2777
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	SSX2 promotes the formation of a novel type of intranuclear lamin bodies. International Journal of Biochemistry and Cell Biology, 2022, 142, 106121.	1.2	1
2	ZBED1 Regulates Genes Important for Multiple Biological Processes of the Placenta. Genes, 2022, 13, 133.	1.0	2
3	MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. Npj Breast Cancer, 2021, 7, 2.	2.3	7
4	HMGA2 as a Critical Regulator in Cancer Development. Genes, 2021, 12, 269.	1.0	91
5	MiR-142-3p targets HMGA2 and suppresses breast cancer malignancy. Life Sciences, 2021, 276, 119431.	2.0	32
6	Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes. Molecular Oncology, 2021, 15, 3299-3316.	2.1	5
7	HMGA2 Supports Cancer Hallmarks in Triple-Negative Breast Cancer. Cancers, 2021, 13, 5197.	1.7	11
8	miRâ€330 suppresses EMT and induces apoptosis by downregulating HMGA2 in human colorectal cancer. Journal of Cellular Physiology, 2020, 235, 920-931.	2.0	51
9	Novel Insights Into Epigenetic Reprogramming and Destabilization of Pericentromeric Heterochromatin in Cancer. Frontiers in Oncology, 2020, 10, 594163.	1.3	4
10	CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens. Frontiers in Immunology, 2020, 11, 1568.	2.2	20
11	Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness. Expert Opinion on Therapeutic Targets, 2020, 24, 255-265.	1.5	30
12	Augmenting engineered T-cell strategies in solid cancers through epigenetic priming. Cancer Immunology, Immunotherapy, 2020, 69, 2169-2178.	2.0	4
13	Interaction between Polycomb and SSX Proteins in Pericentromeric Heterochromatin Function and Its Implication in Cancer. Cells, 2020, 9, 226.	1.8	7
14	The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors. Frontiers in Oncology, 2020, 10, 584024.	1.3	7
15	Identification of miRNAs correlating with stage and progression of colorectal cancer. Colorectal Cancer, 2019, 8, CRC06.	0.8	11
16	A functional genetic screen identifies the Mediator complex as essential for SSX2-induced senescence. Cell Death and Disease, 2019, 10, 841.	2.7	4
17	Remodeling and destabilization of chromosome 1 pericentromeric heterochromatin by SSX proteins. Nucleic Acids Research, 2019, 47, 6668-6684.	6.5	18
18	Photodynamic therapy for cancer: Role of natural products. Photodiagnosis and Photodynamic Therapy, 2019, 26, 395-404.	1.3	128

#	Article	IF	Citations
19	MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis. Free Radical Biology and Medicine, 2019, 139, 1-15.	1.3	128
20	miRâ€142â€3p is a tumor suppressor that inhibits estrogen receptor expression in ERâ€positive breast cancer. Journal of Cellular Physiology, 2019, 234, 16043-16053.	2.0	41
21	HMGA2 and Bachâ€1 cooperate to promote breast cancer cell malignancy. Journal of Cellular Physiology, 2019, 234, 17714-17726.	2.0	33
22	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Clinical Cancer Research, 2019, 25, 7046-7057.	3.2	56
23	miRâ€142â€3p as tumor suppressor miRNA in the regulation of tumorigenicity, invasion and migration of human breast cancer by targeting Bachâ€1 expression. Journal of Cellular Physiology, 2019, 234, 9816-9825.	2.0	100
24	Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells. Nature Communications, 2018, 9, 785.	5.8	29
25	Epigenetic Reprogramming of Pericentromeric Satellite DNA in Premalignant and Malignant Lesions. Molecular Cancer Research, 2018, 16, 417-427.	1.5	22
26	Human DREF/ZBED1 is a nuclear protein widely expressed in multiple cell types derived from all three primary germ layers. PLoS ONE, 2018, 13, e0205461.	1.1	6
27	Ectopic Expression of Testis Germ Cell Proteins in Cancer and Its Potential Role in Genomic Instability. International Journal of Molecular Sciences, 2016, 17, 890.	1.8	37
28	The role of GAGE cancer/testis antigen in metastasis: the jury is still out. BMC Cancer, 2016, 16, 7.	1.1	12
29	Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget, 2015, 6, 15772-15787.	0.8	265
30	Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene, 2015, 34, 1919-1927.	2.6	69
31	Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability. Molecular Oncology, 2015, 9, 437-449.	2.1	33
32	Lack of ADAM2, CALR3 and SAGE1 Cancer/Testis Antigen Expression in Lung and Breast Cancer. PLoS ONE, 2015, 10, e0134967.	1.1	11
33	SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression. Nucleic Acids Research, 2014, 42, 11433-11446.	6.5	21
34	Gene expression profiling for identification of FYN in tamoxifen resistance and as predictor of early recurrence in patients treated with endocrine therapy.. Journal of Clinical Oncology, 2014, 32, 580-580.	0.8	0
35	Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. BMC Cancer, 2013, 13, 466.	1.1	32
36	Limited <scp>SP17</scp> expression within tumors diminishes itsÂtherapeutic potential. Tissue Antigens, 2012, 80, 523-527.	1.0	10

#	Article	IF	Citations
37	GAGE Cancer-Germline Antigens Are Recruited to the Nuclear Envelope by Germ Cell-Less (GCL). PLoS ONE, 2012, 7, e45819.	1.1	14
38	Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer, 2011, 14, 219-225.	2.7	21
39	Cancerâ€“germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment. Expert Opinion on Biological Therapy, 2010, 10, 1061-1075.	1.4	19
40	Expression, purification and characterization of the cancer-germline antigen GAGE12I: A candidate for cancer immunotherapy. Protein Expression and Purification, 2010, 73, 217-222.	0.6	4
41	Epigenetic Modulation of Cancer-Germline Antigen Gene Expression in Tumorigenic Human Mesenchymal Stem Cells. American Journal of Pathology, 2009, 175, 314-323.	1.9	24
42	An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members. Tissue Antigens, 2008, 71, 187-192.	1.0	57
43	An enzyme-linked immunosorbent assay (ELISA) for quantification of mouse surfactant protein D (SP-D). Journal of Immunological Methods, 2008, 330, 75-85.	0.6	22
44	Distinct GAGE and MAGE-A expression during early human development indicate specific roles in lineage differentiation. Human Reproduction, 2008, 23, 2194-2201.	0.4	52
45	MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development. Human Reproduction, 2007, 22, 953-960.	0.4	61
46	Identification of genes with altered expression in medullary breast cancer vs. ductal breast cancer and normal breast epithelia. International Journal of Oncology, 2006, 28, 1327.	1.4	9
47	Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. British Journal of Cancer, 2006, 94, 1864-1873.	2.9	54
48	Identification of genes with altered expression in medullary breast cancer vs. ductal breast cancer and normal breast epithelia. International Journal of Oncology, 2006, 28, 1327-35.	1.4	14
49	Assignment of the surfactant protein A gene (SFTPA) to bovine chromosome 28q1.8â†'q1.9 by radiation hybrid mapping. Cytogenetic and Genome Research, 2004, 106, 142C-142C.	0.6	2
50	The genes encoding bovine SP-A, SP-D, MBL-A, conglutinin, CL-43 and CL-46 form a distinct collectin locus onBos tauruschromosome 28 (BTA28) at position q.1.8-1.9. Animal Genetics, 2004, 35, 333-337.	0.6	28
51	Genomic and molecular characterization of bovine surfactant protein D (SP-D)1. Molecular Immunology, 2004, 41, 369-376.	1.0	9